Search results for "Hepatocellular carcinoma"


 
Results 1 - 10 of about 39 for "Hepatocellular carcinoma".
Sort by: Relevance | Newest | Oldest

Aspirin use is associated with reduced risk for hepatocellular carcinoma

The findings of a recent meta-analysis provide support for an association between aspirin use and reduced risk for hepatocellular carcinoma but do not warrant use of aspirin as prophylaxis, and more research is needed, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2022/07/22/8.htm
22 Jul 2022

MKSAP Quiz: Hepatocellular carcinoma surveillance after HCV treatment

This month's quiz asks readers to determine the most appropriate biannual surveillance modality for a 62-year-old patient with compensated cirrhosis who was treated for hepatitis C virus (HCV) infection six months ago.
https://gastroenterology.acponline.org/archives/2021/10/22/4.htm
22 Oct 2021

Model including hepatitis B viral load accurately predicts HCC risk in untreated patients

Researchers developed and externally validated a model for predicting hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients who had chronic hepatitis B but would not meet current criteria for antiviral treatment in a study in Taiwan, Korea, and Hong Kong.
https://gastroenterology.acponline.org/archives/2024/09/27/6.htm
27 Sep 2024

Hepatitis D co-infection linked with worse outcomes, higher mortality in hepatitis B

Patients with both hepatitis D and hepatitis B are more than twice as likely to develop hepatocellular carcinoma and decompensation and to die of liver-related causes than those with hepatitis B virus alone, according to a study of Veterans Health Administration data.
https://gastroenterology.acponline.org/archives/2024/09/27/3.htm
27 Sep 2024

Lipophilic statins associated with significantly reduced hepatocellular carcinoma incidence, mortality in hepatitis

Potential benefits of lipophilic statins appeared to be dose- and duration-dependent, with the greatest reduction in hepatocellular carcinoma risk seen with use of a moderate-dose statin for about two years, according to data from a registry of Swedish patients with hepatitis B or C.
https://gastroenterology.acponline.org/archives/2019/08/23/7.htm
23 Aug 2019

Statins associated with reduced mortality risk in hepatocellular carcinoma

Inverse associations between postdiagnosis statin use and cancer-specific and all-cause mortality were consistent for low- and high-dose statins and for a range of time periods after cancer diagnosis.
https://gastroenterology.acponline.org/archives/2019/01/25/2.htm
25 Jan 2019

Regorafenib now FDA-approved to treat hepatocellular carcinoma

Approved use of the drug has been expanded to include treatment of patients with hepatocellular carcinoma who have been treated with sorafenib.
https://gastroenterology.acponline.org/archives/2017/05/26/7.htm
26 May 2017

GLP-1s associated with lower risk of hepatic decompensation than other diabetes drugs

Patients taking glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes had lower risk of hepatocellular carcinoma than those on insulin or sulfonylureas, and hepatic decompensation risk was reduced compared with five comparison diabetes drug classes, a study found.
https://gastroenterology.acponline.org/archives/2024/05/24/2.htm
24 May 2024

Serum ferritin values may improve risk stratification of MASLD patients

Baseline hyperferritinemia occurred in almost one-third of study patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and was associated with higher stages of fibrosis.
https://gastroenterology.acponline.org/archives/2024/01/26/3.htm
26 Jan 2024

Case series describes pouchitis after immune checkpoint inhibitors

Two unusual cases of pouchitis occurred in older men receiving therapy for esophageal squamous cell carcinoma and hepatocellular carcinoma.
https://gastroenterology.acponline.org/archives/2023/08/25/11.htm
25 Aug 2023

Result Page: Prev   1   2   3   4   Next